Pancreatic Cancer

Revolution's stock soared after the US Food and Drug Administration (FDA) approved its revolutionary drug. Will the drug reach Israel, how much will it cost, what will insurance companies do, and what competing products are on the market? Here are the answers.

Former Knesset member and journalist Shelly Yachimovich published an update on her condition and answered questions from the public. She explained how the tumor was diagnosed at an early stage and clarified that the new pancreatic cancer drug is not currently relevant for her.

After revealing her struggle with pancreatic cancer, the journalist and former politician shares the "tsunami of empathy" she received. Now, she answers followers' questions and reveals the rare coincidence that led to the early detection of the disease.

The US Food and Drug Administration (FDA) has approved a new drug, Rasonque, for the treatment of advanced pancreatic cancer. Experts believe this development could significantly improve outcomes for patients facing this deadly disease.

In a social media post, the former Labor Party chair updated that the tumor was removed surgically and she is undergoing chemotherapy to prevent its return: "There is a pretty good chance for this, but I am in a practical mood and at peace even with less optimistic scenarios."

Significant news in the fight against one of the deadliest cancers: a new oral drug has nearly doubled the median survival of patients with metastatic pancreatic cancer who had already received prior treatment, compared to standard chemotherapy. The drug, Daraxonrasib (RMC-6236), was tested in a phase 3 study called RASolute 302, showing a median overall survival of 13.2 months versus 6.7 months...

The Tel Aviv Sourasky Medical Center (Ichilov) and the Israeli biotech company Silenseed have launched a clinical trial for the drug SIL204. This innovative treatment targets the KRAS gene mutation, potentially marking a breakthrough in treating one of the deadliest forms of cancer.

A new drug successfully blocks a protein considered one of the main growth drivers of pancreatic cancer, extending the lives of patients who have exhausted standard treatment options.